Product
Group 4
1 clinical trial
1 indication
Indication
Celiac DiseaseClinical trial
A Phase 1B Open-label/Phase 2 Double-blind Placebo- Controlled Study for Pharmacodynamic (PD) Activity, Pharmacokinetics (PK), Safety, and Tolerability of KAN-101 In Patients With Celiac Disease (CeD)Status: Recruiting, Estimated PCD: 2024-12-31